ESR1 and breast cancer: To assess how low MAGI1 expression levels in ER+ BC patients compare to genomic tests in predicting the risk of recurrence, we used the 21 gene recurrent score (GENE21) [51] as a surrogate for the OncotypeDX recurrence score [52].